Fig. 1: Development of a strategy enabled by platinum-protein interactions to overcome chemoresistance. | Nature Communications

Fig. 1: Development of a strategy enabled by platinum-protein interactions to overcome chemoresistance.

From: Leveraging platinum-protein interactions to overcome chemoresistance

Fig. 1: Development of a strategy enabled by platinum-protein interactions to overcome chemoresistance.

a Key challenges associated with combination therapies using conventional ATP-binding cassette (ABC) transporter inhibitors to overcome multidrug resistance mediated by P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and ATP-binding cassette super-family G member 2 (ABCG2). b Platinum-containing drug conjugates exploit platinum-protein interactions to overcome efflux pump-mediated multidrug resistance without disrupting normal efflux activity. c Synthesis of the doxorubicin-oxaliplatin conjugate, doxaliplatin (DoxPt, 2), with minimal structural modifications to both parental drugs. d Doxaliplatin derivatives with different structural features.

Back to article page